Purpose
To evaluate the effect of ATP-sensitive potassium channel openers cromakalim prodrug 1 (CKLP1) and diazoxide on IOP in three independent mouse models of ocular hypertension.
Methods
Baseline IOP was measured in TGFβ2 overexpression, steroid-induced, and iris dispersion (DBA/2J) ocular hypertension mouse models, followed by once daily eyedrop administration with CKLP1 (5 mM) or diazoxide (5 mM). The IOP was measured in conscious animals with a handheld rebound tonometer. Aqueous humor dynamics were assessed by a constant perfusion method. Effect of treatment on ocular tissues was evaluated by transmission electron microscopy.
Results
CKLP1 decreased the IOP by 20% in TGFβ2 overexpressing mice (
n
= 6;
P
< 0.0001), 24% in steroid-induced ocular hypertensive mice (
n
= 8;
P
< 0.0001), and 43% in DBA/2J mice (
n
= 15;
P
< 0.0001). Diazoxide decreased the IOP by 32% in mice with steroid-induced ocular hypertension (
n
= 13;
P
< 0.0001) and by 41% in DBA/2J mice (
n
= 4;
P
= 0.005). An analysis of the aqueous humor dynamics revealed that CKLP1 decreased the episcleral venous pressure by 29% in TGFβ2 overexpressing mice (
n
= 13;
P
< 0.0001) and by 72% in DBA/2J mice (
n
= 4 control, 3 treated;
P
= 0.0002). Diazoxide lowered episcleral venous pressure by 35% in steroid-induced ocular hypertensive mice (
n
= 3;
P
= 0.03). Tissue histology and cell morphology appeared normal when compared with controls. Accumulation of extracellular matrix was reduced in CKLP1- and diazoxide-treated eyes in the steroid-induced ocular hypertension model.
Conclusions
ATP-sensitive potassium channel openers CKLP1 and diazoxide effectively decreased the IOP in ocular hypertensive animal models by decreasing the episcleral venous pressure, supporting a potential therapeutic application of these agents in ocular hypertension and glaucoma.